IPAR

Publicly Available Assessment Report for a
Veterinary Medicinal Product

Intubeaze 20 mg/ml laryngopharyngeal spray, solution for cats

PRODUCT SUMMARY

EU Procedure number	IE/V/0554/001 (formerly UK/V/0670/001)
Name, strength and pharmaceutical form	Intubeaze 20 mg/ml laryngopharyngeal spray, solution for cats
Active substances(s)	Lidocaine Hydrochloride Monohydrate
Applicant	Dechra Ltd Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW United Kingdom
Legal basis of application	Generic application (Article 13(1) of Directive No 2001/82/EC)
Target species	Cats
Indication for use	Local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing the stimulation of the laryngeal reflex.
ATCvet code	QR02AD02
Date product first authorised in the Reference Member State (MRP only)	26 September 2018 (UK) 07 December 2018 (IE)
Date product first authorised in the Reference Member State (MRP only)	Not Applicable
Concerned Member States	Austria, Belgium, Denmark, Finland, France, Germany, Ireland (now RMS), Italy, Netherlands, Norway, Poland, Portugal, Spain, Sweden UK added via RMS change

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.
The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

This was an application for a generic product, submitted in accordance with Article 13(1) of Directive 2001/82/EC, as amended by 2004/28/EC.
The reference product is Intubeaze 20 mg/ml Oromucosal Spray for Cats, authorised in the UK since September 1996.
The product is indicated for local anaesthesia of the laryngeal mucosa of the cat in order to facilitate endotracheal intubation by preventing the stimulation of the laryngeal reflex.
The product contains lidocaine hydrochloride monohydrate at 20 mg/ml, (equivalent to lidocaine 16.2 mg). Each actuation (0.14 ml contains 2.8 mg of lidocaine hydrochloride monohydrate, which corresponds to 2.27 mg of lidocaine. The product is administered via one or two sprays to the back of the throat.
The product is produced and controlled using validated methods and tests which ensure the consistency of the product released onto the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall benefit/risk analysis is in favour of granting a marketing authorisation

II. QUALITY ASPECTS

II.A. Composition
The product contains lidocaine hydrochloride and the excipients sodium chloride, chlorocresol and water for injections.
The container/closure system consists of type 1 clear glass vials sealed with a spray pump. The particulars of the containers and controls performed are provided and conform to the regulation.
The choice of the formulation and the presence of preservative are not justified. This is the same as the reference product, therefore acceptable.
The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method
The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of a simple dissolution process whereby the excipients are dissolved then heated to 50 - 60 ºC. Once cooled, the active substance is then added and dissolved. The solution is made to volume with water for injections and re-mixed.
Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials
The active substance is lidocaine hydrochloride an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided. Suitable Certificates of Analysis were provided.
All excipients are monographed within the European Pharmacopoeia (Ph. Eur).
The container for the product is a glass vial sealed with a spray pump.

II.C.4. Substances of Biological Origin
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process
Not applicable

II.E. Control Tests on the Finished Product
The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification. Control tests on the finished product include those for: description, identification, pH, assay, average spray volume, spray uniformity, spray pattern, total viable count, absence of *Pseudomonas aeruginosa* and *Staphylococcus aureus*.

II.F. Stability
Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

G. Other Information
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening: 3 months
The product should not be stored above 25°C

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Documentation
Pharmacological Studies
Due to the legal basis of this application, pharmacological and toxicological data are not required, other than to support the user risk assessment (URA).

Toxicological Studies
Due to the legal basis of this application, pharmacological and toxicological data are not required, other than to support the user risk assessment (URA).

User Safety
A user risk assessment was provided in compliance with the relevant guideline which shows that the product will only be administered by veterinarians or similarly qualified people and will only be used in veterinary clinics or similar controlled environments.
Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

> Lidocaine and Chlorocresol may cause hypersensitivity (allergic) reactions. People with known hypersensitivity to these substances should avoid contact with the product.
> Accidental exposure to this product may lead to local effects such as numbing, and systemic effects, such as dizziness or drowsiness. Accidental exposure, particularly oral, eye and inhalation exposure, should be avoided.
> Wear gloves when handling the product and wash any exposed areas after use. If accidental exposure to eyes occurs, rinse with water.
> In cases of severe or extended reactions, seek medical advice and show the label to the physician.
> Lidocaine can form genotoxic and mutagenic metabolites in humans. These metabolites can also induce, in long-term toxicology studies in rats, carcinogenic effects at high doses.

Environmental Safety
The applicant has submitted a Phase I ERA conducted in accordance with current VICH and CVMP guidelines. The assessment has concluded at question 3 of the decision tree, as the product will be used in non-food producing animals only. A Phase II ERA was not required.
The disposal advice and environmental warnings found under section 6.6 of the SPC and package leaflet are as follows:

- Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

IV. CLINICAL ASSESSMENT

IV.I. Pre-Clinical Studies
Pharmacology
As this product is a generic, the applicant has not provided data pharmacodynamic and pharmacokinetic properties of the active substance

Tolerance in the Target Species
Tolerance studies were not required as this is a generic product.

IV.II. Clinical Documentation
Laboratory Trials
The applicant has not provided any studies as this is a generic product

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics the benefit/risk profile of the product is favourable